Kanvas Biosciences

Kanvas Biosciences develops a spatial biology platform for breakthroughs in drug development, clinical diagnostics, agriculture, and food safety. Its proprietary technology maps gene expression and cellular function, focusing on host-microbiome interactions to create live biotherapeutic products (LBPs) for treating microbiome-associated diseases. The company is particularly focused on improving immunotherapy efficacy for cancer patients.

Funding Round: Series A

Funding Amount: $12.5M

Date: 01-Jul-2024

Investors: DCVC, Lions Capital LLC, FemHealth Ventures, Germin8, Ki Tua Fund, Pangaea Ventures

Markets: Biotechnology, Therapeutics, Immuno-oncology, Microbiology, Life Science, Drug Discovery, Digital Health, HealthTech, Oncology

HQ: Monmouth Junction, New Jersey, United States

Founded: 2020

Website: https://www.kanvasbio.com/

LinkedIn: https://www.linkedin.com/company/kanvas-biosciences/

Twitter: https://twitter.com/kanvasbio

Instagram:

Facebook: